Gritstone Bio Analyst Ratings
Gritstone Bio Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/07/2022 | 165.15% | HC Wainwright & Co. | $12 → $7 | Maintains | Buy |
| 10/31/2022 | 127.27% | Piper Sandler | → $6 | Initiates Coverage On | → Overweight |
| 08/22/2022 | -24.24% | Goldman Sachs | → $2 | Downgrades | Neutral → Sell |
| 05/09/2022 | 354.55% | HC Wainwright & Co. | $15 → $12 | Maintains | Buy |
| 03/14/2022 | 468.18% | HC Wainwright & Co. | $24 → $15 | Maintains | Buy |
| 01/20/2021 | 203.03% | Baird | → $8 | Downgrades | Outperform → Underperform |
| 01/20/2021 | 809.09% | HC Wainwright & Co. | $16 → $24 | Maintains | Buy |
| 07/14/2020 | 543.94% | BTIG | $31 → $17 | Maintains | Buy |
| 07/26/2019 | 543.94% | Baird | → $17 | Initiates Coverage On | → Outperform |
| 03/15/2019 | 657.58% | Raymond James | → $20 | Initiates Coverage On | → Outperform |
| 03/07/2019 | 543.94% | HC Wainwright & Co. | → $17 | Initiates Coverage On | → Buy |
| 10/23/2018 | — | Cowen & Co. | Initiates Coverage On | → Outperform | |
| 10/23/2018 | 581.82% | Goldman Sachs | → $18 | Initiates Coverage On | → Neutral |
| 10/23/2018 | 884.85% | BTIG | → $26 | Initiates Coverage On | → Buy |
| 10/23/2018 | 846.97% | Barclays | → $25 | Initiates Coverage On | → Overweight |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 2022 年 7 月 11 日 | 165.15% | HC Wainwright & Co. | 12 美元 → 7 美元 | 維護 | 買 |
| 10/31/2022 | 127.27% | 派珀·桑德勒 | → 6 美元 | 啓動覆蓋範圍開啓 | → 超重 |
| 2022 年 8 月 22 日 | -24.24% | 高盛 | → 2 美元 | 降級 | 中性 → 賣出 |
| 05/09/2022 | 354.55% | HC Wainwright & Co. | 15 美元 → 12 美元 | 維護 | 買 |
| 03/14/2022 | 468.18% | HC Wainwright & Co. | 24 美元 → 15 美元 | 維護 | 買 |
| 2021 年 1 月 20 日 | 203.03% | 貝爾德 | → 8 美元 | 降級 | 跑贏大盤 → 表現不佳 |
| 2021 年 1 月 20 日 | 809.09% | HC Wainwright & Co. | 16 美元 → 24 美元 | 維護 | 買 |
| 2020 年 7 月 14 日 | 543.94% | BTIG | 31 美元 → 17 美元 | 維護 | 買 |
| 07/26/2019 | 543.94% | 貝爾德 | → 17 美元 | 啓動覆蓋範圍開啓 | → 跑贏大盤 |
| 03/15/2019 | 657.58% | 雷蒙德·詹姆 | → 20 美元 | 啓動覆蓋範圍開啓 | → 跑贏大盤 |
| 2019 年 7 月 3 日 | 543.94% | HC Wainwright & Co. | → 17 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 10/23/2018 | — | Cowen & Co. | 啓動覆蓋範圍開啓 | → 跑贏大盤 | |
| 10/23/2018 | 581.82% | 高盛 | → 18 美元 | 啓動覆蓋範圍開啓 | → 中立 |
| 10/23/2018 | 884.85% | BTIG | → 26 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 10/23/2018 | 846.97% | 巴克萊 | → 25 美元 | 啓動覆蓋範圍開啓 | → 超重 |
Gritstone Bio Questions & Answers
Gritstone 生物問答
The latest price target for Gritstone Bio (NASDAQ: GRTS) was reported by HC Wainwright & Co. on November 7, 2022. The analyst firm set a price target for $7.00 expecting GRTS to rise to within 12 months (a possible 165.15% upside). 5 analyst firms have reported ratings in the last year.
HC Wainwright & Co. 於2022年11月7日公佈了Gritstone Bio（納斯達克股票代碼：GRTS）的最新目標股價。該分析公司將目標股價定爲7.00美元，預計GRTS將在12個月內升至12個月內（可能上漲165.15％）。去年有5家分析公司公佈了評級。
The latest analyst rating for Gritstone Bio (NASDAQ: GRTS) was provided by HC Wainwright & Co., and Gritstone Bio maintained their buy rating.
HC Wainwright & Co. 對Gritstone Bio（納斯達克股票代碼：GRTS）的最新分析師評級由HC Wainwright & Co. 提供，Gritstone Bio維持買入評級。
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Gritstone Bio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Gritstone Bio was filed on November 7, 2022 so you should expect the next rating to be made available sometime around November 7, 2023.
分析師在進行了廣泛的研究後得出了股票評級，其中包括瀏覽公開財務報表，與Gritstone Bio的高管和客戶交談，以及聽取業績電話會議。大多數分析師每三個月做一次這樣的評級，因此每家公司每年應該獲得4次評級。Gritstone Bio的最新評級是在2022年11月7日發佈的，因此您應該預計下一個評級將在2023年11月7日左右公佈。
While ratings are subjective and will change, the latest Gritstone Bio (GRTS) rating was a maintained with a price target of $12.00 to $7.00. The current price Gritstone Bio (GRTS) is trading at is $2.64, which is out of the analyst's predicted range.
儘管評級是主觀的，並且會發生變化，但最新的Gritstone Bio（GRTS）評級保持不變，目標股價爲12.00美元至7.00美元。Gritstone Bio（GRTS）目前的交易價格爲2.64美元，超出了分析師的預期區間。